MedTrace Logo

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

NCT06635954 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-03-17

No results posted yet for this study

Summary

The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.

Conditions

  • Cancer
  • Immunotherapy
  • PD-1
  • PD-L1
  • Immune Checkpoint Therapy

Sponsors & Collaborators

  • Community Clinical Oncology Research Network, LLC

    collaborator UNKNOWN

  • Oxford Biodynamics Inc.

    lead INDUSTRY

Principal Investigators

  • Ryan Mathis, MD · Oxford BioDynamics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-14
Primary Completion
2026-05-14
Completion
2027-05-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06635954 on ClinicalTrials.gov